lynparza 50mg


Description


Lynparza is a prescription drug which used under the supervision of medical practioners.
Olaparib is generic form of brand name Lynparza anditis ankind of oral poly (adenosine diphosphate–ribose) polymerase inhibitor which has promising antitumor action in patients with metastatic breast cancer and a germline BRCA mutation.


Indication


Lynparza is indicated for the treatment in patients with
Advanced ovarian cancer as founded who have been treated with three or more prior lines of chemotherapy
HER2 – negative metastatic breast cancer who have been treated with chemotherapy.


ADME


Lynparza has time to peak plasma concentration 1 to 3 hours
volume of distribution 167 +/-196 L, plasma protein binding is 82%
Primarily metabolised by CYP3A4
Lynparza Excreted through the urine 44% and 42% through the feces.
Half – life of Lynparza 11.9 hours.







Mechanism Of Action


Olaparib belongs to targeted therapy. Which contain PARP1, PARP2, and PARP3. PARP enzymes are included in DNA transcription, cell cycle managing, and DNA repair. Olaparib is an efficient oral PARP inhibitor that induces synthetic lethality in BRCA 1/2 deficient tumor cells through the formation of double-stranded DNA cut off which cannot be specifically repaired, which cause disruption of cellular homeostasis and cell death.

Dosage and administration


Ovarian cancer :
Maintenance treatment of recurrent ovarian cancer:
The tablet recommended dose is 300mg (two 150mg – mg tablets) PO BID
Continue treatment until disease progression or unacceptable toxicity
Monotherapy for advanced BRCA – mutated ovarian cancer :
The tablet recommended dose is 300mg (two 150mg – mg tablets) PO BID
The capsules recommended dose is 400mg (eight 50mg- mg capsules) PO BID
Continue treatment until disease progression or unacceptable toxicity.
Maintenance treatment for advanced BRCA-mutated ovarian cancer:
The tablet recommended dose is 300mg (two 150mg – mg tablets) PO BID
Follow the treatment until disease progression, undesirable toxicity or completion of 2 years of treatment
Finishing of 2 years of treatment :
• Patients with full response (no radiologic evidence): discontinue treatment
• Patients with indication of disease and may asset from continuous treatment: cure beyond 2 years.
Breast cancer:
The recommended dose is 300mg (two 150mg – mg tablets) PO BID.

Precautions


• When Lynparza monotherapy administrated to patient the incidence of myelodysplastic syndrome will occur.
• Haematological toxicity will cause in patients treated with Lynparza contain diagnoses or findings of generally mild or moderate anaemia, neutropenia, thrombocytopenia and lymphopenia.
• On basis of mechanism of action (PARP inhibition), Lynparza could cause risk to fetal when administered to a pregnant woman.
Lynparza combination with strong or moderate CYP3A inhibitors is not recommended.

Pregnancy


Based on Lynparza mechanism of action, the drug causes risk to the fetal may occur when administrated to a pregnant woman.

Side Effects


Common side effects :
• low white blood cell count
• Abdominal pain
• Vomiting
• Upper respiratory tract infection
• Anemia
• low neutrophils
• Musculoskeletal pain.
Less common side effects:
• Muscle pain
• Pain in head
• rash on Skin
• Back pain
• Taste changes
• Cough
• Swelling
• Dizziness
• Constipation
• Urinary tract infection
• Heartburn
• Decreased appetite
• Shortness of breath.

Missed Dose


If dose is missed the have the dose immediately before next dose timing reaches or skip the missed dose and continue the regular schedule. Consult doctors regarding missed dose.



Lactation


No data available on the presence of Lynparza in human milk, hence avoid breast feeding during the treatment.


Storage


Store at 200C to 250C.


Contraindication


None


Connect With Us

Prescription Medication Policy


1. Anti-Cancer-Drugs.com, a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. Anti-Cancer-Drugs.com will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the Anti-Cancer-Drugs.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. Anti-Cancer-Drugs.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Anti-Cancer-Drugs.com
6. At Anti-Cancer-Drugs.com, a Caregiver can order prescription medicines on your behalf.